Literature DB >> 2575598

Coexistence of antigen-specific TH1 and TH2 cells in genetically susceptible BALB/c mice infected with Leishmania major.

M Lohoff1, F Sommer, W Solbach, M Röllinghoff.   

Abstract

CD4-positive T cell clones with specificity for the protozoan parasite Leishmania major (L. major) of both the protective TH1 and the disease-exacerbating TH2 subtype were isolated from a diseased L. major-infected mouse of the susceptible BALB/c strain. In addition, TH2 cells were isolated from the lesion-draining lymph nodes of an animal clinically healed nine months after sublethal irradiation and subsequent infection. Our data support the notion that the differential outcome of the disease in non-irradiated versus irradiated BALB/c mice reflects the regulation of the two CD4+ T cell subsets. These data also argue against the possibilities that: 1) TH2 cells and their precursors are totally eliminated by irradiation and that 2) TH2 cells are capable of completely hindering the expansion of TH1 cells in diseased animals.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2575598     DOI: 10.1016/S0171-2985(89)80045-2

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  13 in total

1.  Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression.

Authors:  Levi H C Makala; Babak Baban; Henrique Lemos; Ahmed R El-Awady; Phillip R Chandler; De-Yan Hou; David H Munn; Andrew L Mellor
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

2.  T cells from Leishmania major-susceptible BALB/c mice have a defect in efficiently up-regulating CXCR3 upon activation.

Authors:  Joseph Barbi; Frank Brombacher; Abhay R Satoskar
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

3.  Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis.

Authors:  F P Heinzel; M D Sadick; S S Mutha; R M Locksley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

4.  Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis.

Authors:  M Kemp; J A Kurtzhals; K Bendtzen; L K Poulsen; M B Hansen; D K Koech; A Kharazmi; T G Theander
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

5.  Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam.

Authors:  G S Nabors; L C Afonso; J P Farrell; P Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

6.  Multiple closely-linked NFAT/octamer and HMG I(Y) binding sites are part of the interleukin-4 promoter.

Authors:  S Chuvpilo; C Schomberg; R Gerwig; A Heinfling; R Reeves; F Grummt; E Serfling
Journal:  Nucleic Acids Res       Date:  1993-12-11       Impact factor: 16.971

7.  Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients.

Authors:  J A Kurtzhals; A S Hey; A Jardim; M Kemp; K U Schaefer; E O Odera; C B Christensen; J I Githure; R W Olafson; T G Theander
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

Review 8.  Th1/Th2 balance in infection.

Authors:  C Infante-Duarte; T Kamradt
Journal:  Springer Semin Immunopathol       Date:  1999

9.  The role of indoleamine 2, 3 dioxygenase in regulating host immunity to leishmania infection.

Authors:  Levi H C Makala
Journal:  J Biomed Sci       Date:  2012-01-09       Impact factor: 8.410

10.  Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity.

Authors:  F Powrie; R Correa-Oliveira; S Mauze; R L Coffman
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.